Granisetron
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Granisetron: From Antiemetic Use to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist used clinically as an antiemetic; a formally documented original indication and mechanism-of-action record are not present in this evidence pack (flagged as data gaps). The TxGNN model predicts it may be effective for Manic Bipolar Affective Disorder, but this direction is currently supported by 0 clinical trials and 0 publications — a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antiemetic (nausea/vomiting) — specific approved-indication text unavailable; drug has no license records in this jurisdiction |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for granisetron is not available in structured form in this evidence pack (High-severity data gap, DG002). Based on the mechanistic notes accompanying this prediction, granisetron is described as a selective 5-HT3 (serotonin) receptor antagonist, classically used as an antiemetic.
The proposed link to manic bipolar affective disorder rests on a theoretical relationship between the 5-HT3 pathway and mood regulation via the limbic system. Other 5-HT3 antagonists (e.g., ondansetron) have been explored in small, exploratory studies for mood disorders, which lends some biological plausibility. However, there is no direct clinical evidence — no trials and no publications in this evidence pack — supporting granisetron's use in the manic phase of bipolar disorder. This connection should be treated as mechanistic inference only, not a clinically validated signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
The drug is not marketed and no authorization records are available (total_licenses = 0).
Safety Considerations
Please refer to the package insert for safety information.
Note: Full safety review is currently blocked — TFDA-equivalent package-insert warnings/contraindications and drug-drug interaction data are not yet available (Blocking data gap, DG001), so this candidate cannot proceed past a preliminary S0/S1 safety screen.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5) with zero clinical trials or literature, the drug is not currently marketed, and safety evaluation is blocked by a missing package-insert dataset (DG001). There is insufficient evidence to advance this candidate.
To proceed, the following is needed:
- TFDA (or equivalent) package insert warnings and contraindications (DG001, Blocking)
- Confirmed mechanism-of-action documentation from DrugBank or primary literature (DG002, High)
- At minimum, preclinical/mechanistic or case-level literature specifically linking 5-HT3 antagonism to bipolar mania before any clinical evaluation is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.